MedTrace Logo

Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

NCT00254735 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2007-12-18

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

quetiapine fumarate

DRUG

SSRI/Clomipramine

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Germany Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Completion
2006-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00254735 on ClinicalTrials.gov